Table of Contents

HK J Paediatr (New Series)
Vol 9. No. 3, 2004

HK J Paediatr (New Series) 2004;9:272

Proceedings of Conference

Bone Marrow Transplantation for Lysosomal Storage Disease

A Vellodi


HK J Paediatr (new series) 2004;9:253-276

Conference of Inborn Errors of Metabolism in Infants and Children 2002
Hong Kong Society of Neonatal Medicine, Hong Kong Society of Medical Genetics, Hong Kong Society of Clinical Chemistry, Hong Kong Society of Paediatric Endocrinology & Metabolism, Hong Kong Nutrition Association and Obstetrical and Gynaecological Society of Hong Kong

Bone marrow transplant as a form of treatment for lysosomal storage diseases offers hope for amelioration of the course of the disease. However, it carries high morbidity and/or mortality. This is an important modality of treatment when there is no alternative therapy available.

In lysosomal storage diseases, enzyme deficiency results in accumulation of substrate. Bone marrow transplant works by repopulating the marrow with enzyme-producing cells, which then disseminate into the reticulo-endothelial systems in different parts of the body. There is also evidence that enzyme is transferred from these cells to other enzyme-deficient cells. Enzyme-producing marrow stem cells also turn into microglial cells in the brain and potentially prevent neurological deterioration in some transplanted patients.

The experience of bone marrow transplant is most abundant in mucopolysaccharidosis I (MPS-I). There is adequate response in central nervous system, heart, respiratory system and hearing. However, the response in the eyes, bone and cartilage remains inadequate. With accumulation of experience, it is generally agreed that bone marrow transplant in MPS-I should be done if the following criteria are satisfied:

  1. Age <18 months and preferably < 12 months.
  2. Absence of significant hydrocephalus.
  3. Parental understanding of limitation of bone marrow transplant.

Cardiomyopathy is not a contraindication for transplant although the mortality of transplant in its presence is increased. The genotype and residual enzyme activity need to be studied as these offer some prediction as to the severity of the disease progression.

In mucopolysaccharidosis II (MPS-II), the value of bone marrow transplant is less clear. Unlike MPS-I, the diagnosis of MPS-II tends to be delayed. Outcome of some previously transplanted cases is not impressive. In mucopoly-saccharidosis III, bone marrow transplant is incapable of altering its course. Bone marrow transplant has a definite role in the treatment of adrenoleukodystrophy preventing progressive deterioration.

In conclusion, bone marrow transplant does not result in normality. It works better in slowly progressive disorders. Alternative therapy like enzyme replacement therapy may complement BMT in the management of lysosomal storage disorders.

 
 

This web site is sponsored by Johnson & Johnson (HK) Ltd.
©2024 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.